<?xml version="1.0" encoding="UTF-8"?>
<AssessmentQuestion xmlns="http://soap.sforce.com/2006/04/metadata">
    <assessmentQuestionVersion>
        <isActive>true</isActive>
        <name>XLHBurosumab_InitialRenewal_COVERAGE_CRITERIA_Q1</name>
        <optionSourceResponseValue>false</optionSourceResponseValue>
        <questionText>Initiation Criteria
1. Treatment can be initiated in pediatric patients who are at least one year of age and in whom epiphyseal closure has not yet occurred, who have:
1.1. a clinical presentation consistent with XLH, including:
 1.1.1. fasting hypophosphatemia, and
 1.1.2. normal renal function (defined as fasting serum creatinine below the age-adjusted upper limit of normal), and
1.2. radiographic evidence of rickets with a rickets severity score (RSS) total score of two or greater, and
1.3. a confirmed phosphate-regulating endopeptidase homolog, X-linked (PHEX) gene variant in either the patient or in a directly related family member with appropriate X-linked inheritance. 

Renewal Criteria
1. Patients should be assessed on an annual basis. Treatment with burosumab can be renewed as long as the patient does not meet any of the following discontinuation criteria.

Discontinuation Criteria
1. In pediatric patients in whom epiphyseal closure has not yet occurred, reimbursement of treat</questionText>
        <status>Active</status>
        <versionNumber>1</versionNumber>
    </assessmentQuestionVersion>
    <dataType>TextBlock</dataType>
    <developerName>XLHBurosumab_InitialRenewal_COVERAGE_CRITERIA_Q1</developerName>
    <name>XLHBurosumab_InitialRenewal_COVERAGE_CRITERIA_Q1</name>
    <questionCategory>Demographic</questionCategory>
</AssessmentQuestion>
